ClinicalTrials.gg
CompletedNCT00374868Updated Nov 4, 2010Results posted

Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)

A Phase 1/2 interventional study of pemetrexed and cisplatin in Urologic Neoplasms, sponsored by Eli Lilly and Company. Completed at 5 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-04.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Urologic Neoplasms with a site in Spain — 3 open to participants now, 6 under way, none of them phase 3. Urologic Neoplasms · Spain.

Enrollment
13th of 14
59 · median 265
Started
2006
the only one that year
Phase 1/2
3 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
4 of 15
Eli Lilly and Company

Among the 15 studies in Urologic Neoplasms with a site in Spain, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2006, is one of 3 in phase 1/2, and was the 1st registered.

Urologic Neoplasms

155 studies on the registry are indexed under Urologic Neoplasms; 40 are open to participants now.

Browse Urologic Neoplasms studies →

Open to participants now

3 of the 15 studies in Urologic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 30 Urologic Neoplasms studies recruiting now, 24 (80%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Urologic Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

To assess the anti-tumor activity, as measured by response rate to bi-weekly pemetrexed plus cisplatin, in chemo-naive patients with diagnosed metastatic or locally advanced (non-resectable) urothelial cancer.

03

Conditions studied

  • Urologic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven locally advanced disease or transitional cell carcinoma of the urothelium including bladder, urethra, ureter, and renal pelvis. Patients should not be suitable for surgery or radiation with curative intent. However patients whose pre-chemotherapy sites of disease are restricted to the primary or regional lymph node sites and who have a major response to chemotherapy will be evaluated for post-chemotherapy surgical resection of residual cancer if the tumor has become resectable at the end of chemotherapy.
  • status, as defined in the (RECIST) criteria (Therasse et al., 2000)
  • One course of prior radiation therapy is allowed. Prior radiation must have been completed at least 4 weeks before enrolment into the study and the patients must have recovered from all toxic effects.

Exclusion criteria

Exclusion Criteria:

  • Have central nervous system (CNS) or (unless the patient has completed successful local therapy for and has been off for at least 4 weeks before starting study therapy). A screening computed tomography (CT) or magnetic resonance imaging (MRI) before enrollment in the absence of a clinical suspicion of brain metastases is not required.
  • Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents 2 days before, the day of, and 2 days after the dose of pemetrexed plus cisplatin or cisplatin alone. If a patient is taking a nonsteroidal anti-inflammatory drug (NSAID) or salicylate with a long half-life (for example, naproxen, piroxicam, diflunisal) it should not be taken 5 days before the dose of pemetrexed (8-day period for long-acting agents such as piroxicam), the day of, and 2 days after the dose of pemetrexed plus cisplatin.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Pemetrexed + Cisplatin

    Drug: pemetrexed · Drug: cisplatin

Interventions

  • Phase 1: 300 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m\^2, 400 mg/m\^2, and 500 mg/m\^2) Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy

    Also known as: LY231514, Alimta

  • Phase 1: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles Phase 2: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy

06

What researchers measure

Primary outcomes

  1. Best Overall Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.

    Time frame: baseline to measured progressive disease (up to 620 days)

Secondary outcomes

  1. Time to Response

    Defined as time from study enrollment to the first Complete Response or Partial Response (using RECIST criteria). Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.

    Time frame: baseline to response (up to 620 days)

  2. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.

    Time frame: time of response to progressive disease (up to 620 days)

  3. Duration of Stable Disease

    Defined as time from study enrollment to the first progression of disease, complete response, partial response, or death from any cause. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.

    Time frame: time of no response or progression (up to 620 days)

  4. Time to Progressive Disease

    Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions.

    Time frame: baseline to measured progressive disease (up to 620 days)

  5. Time to Treatment Failure (TTF)

    Time from study enrollment to first observation of disease progression, death from any cause, or early discontinuation of treatment (including toxicity or if patient had stable disease after 4 cycles). TTF was censored at date of last follow-up visit for patients who did not discontinue early, who were still alive, and who had not progressed.

    Time frame: baseline to stopping treatment (up to 620 days)

  6. Progression-Free Survival

    Defined as the time from study enrollment until disease progression or death from any cause.

    Time frame: baseline to measured progressive disease (up to 620 days)

  7. Overall Survival

    Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

    Time frame: baseline to date of death from any cause (up to 620 days)

07

Results

Posted Jun 17, 2009

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Cisplatin
Started38
Completed2
Not completed36
Withdrew: Adverse event12
Withdrew: Progressive disease7
Withdrew: Physician decision13
Withdrew: Lost to follow-up1
Withdrew: Death2
Withdrew: Other - not specified1

Outcome measures

PrimaryBest Overall Tumor Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.

Time frame:
baseline to measured progressive disease (up to 620 days)
Reported as:
Number · participants
Best Overall Tumor Response
participantsPemetrexed + Cisplatin
Complete Response2
Partial Response13
Stable Disease13
Progressive Disease1
Not Evaluated3
Not Performed3
Missing3
SecondaryTime to Response

Defined as time from study enrollment to the first Complete Response or Partial Response (using RECIST criteria). Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.

Time frame:
baseline to response (up to 620 days)
Reported as:
Mean · days
Time to Response
daysPemetrexed + Cisplatin
Time to Response111.816 ± 6.480
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.

Time frame:
time of response to progressive disease (up to 620 days)
Reported as:
Mean · days
Duration of Response
daysPemetrexed + Cisplatin
Duration of Response184.100 ± 19.595
SecondaryDuration of Stable Disease

Defined as time from study enrollment to the first progression of disease, complete response, partial response, or death from any cause. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.

Time frame:
time of no response or progression (up to 620 days)
Reported as:
Median · days
Duration of Stable Disease
daysPemetrexed + Cisplatin
Duration of Stable Disease80 (71 to 103)
SecondaryTime to Progressive Disease

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions.

Time frame:
baseline to measured progressive disease (up to 620 days)
Reported as:
Mean · days
Time to Progressive Disease
daysPemetrexed + Cisplatin
Time to Progressive Disease260.182 ± 22.954
SecondaryTime to Treatment Failure (TTF)

Time from study enrollment to first observation of disease progression, death from any cause, or early discontinuation of treatment (including toxicity or if patient had stable disease after 4 cycles). TTF was censored at date of last follow-up visit for patients who did not discontinue early, who were still alive, and who had not progressed.

Time frame:
baseline to stopping treatment (up to 620 days)
Reported as:
Median · days
Time to Treatment Failure (TTF)
daysPemetrexed + Cisplatin
Time to Treatment Failure (TTF)133.5 (99 to 151)
SecondaryProgression-Free Survival

Defined as the time from study enrollment until disease progression or death from any cause.

Time frame:
baseline to measured progressive disease (up to 620 days)
Reported as:
Median · days
Progression-Free Survival
daysPemetrexed + Cisplatin
Progression-Free Survival203 (137 to 285)
SecondaryOverall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

Time frame:
baseline to date of death from any cause (up to 620 days)
Reported as:
Mean · days
Overall Survival
daysPemetrexed + Cisplatin
Overall Survival264.190 ± 15.130

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Cisplatin———
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPemetrexed + Cisplatin
NeutropeniaBlood and lymphatic system disorders4/38
Deep vein thrombosisVascular disorders4/38
LeukopeniaBlood and lymphatic system disorders3/38
DiarrhoeaGastrointestinal disorders3/38
VomitingGastrointestinal disorders3/38
PyrexiaGeneral disorders3/38
Urinary tract infectionInfections and infestations3/38
NauseaGastrointestinal disorders2/38
Renal failureRenal and urinary disorders2/38
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/38
Most frequent other events
Showing 10 of 58
Most frequent other events
EventPemetrexed + Cisplatin
AstheniaGeneral disorders29/38
NauseaGastrointestinal disorders20/38
VomitingGastrointestinal disorders20/38
AnorexiaMetabolism and nutrition disorders19/38
DiarrhoeaGastrointestinal disorders18/38
Mucosal inflammationGeneral disorders14/38
Abdominal painGastrointestinal disorders10/38
ConstipationGastrointestinal disorders10/38
AnaemiaBlood and lymphatic system disorders8/38
Back painMusculoskeletal and connective tissue disorders7/38

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed + Cisplatin
Mean67.1 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + Cisplatin
Female7
Male31
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + Cisplatin
Spain38
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Pemetrexed + Cisplatin
0 - Fully Active21
1 - Ambulatory, Restricted Strenuous Activity15
2 - Ambulatory, No Work Activities2
Location of Primary Tumor
Location of Primary Tumor(participants)Pemetrexed + Cisplatin
Bladder32
Ureter1
Urethra1
Renal Pelvis4
Height
Height(centimeters)Pemetrexed + Cisplatin
Mean166 ± 7.5
Weight
Weight(kilograms)Pemetrexed + Cisplatin
Mean77.4 ± 13.2
08

Study locations

5 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28041, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pamplona, 31008, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sabadell, 08208, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santander, 39008, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2006
First posted
Sep 12, 2006
Start
Aug 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Jun 17, 2009
Last update
Nov 4, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00374868
First posted
Sep 12, 2006
Start date
Aug 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jun 17, 2009
Last update
Nov 4, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion